Clinical Study of CM338 in the Treatment of Immunoglobulin A Nephropathy

Abroad (travel likely)RecruitingPHASE2

Conditions

IgA Nephropathy

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Peking University First Hospital, Beijing, Beijing Municipality, China
Contact: Study coordinator (Jicheng Lv) · jichenglv75@gmail.com · 13161753111

Study leads

Jicheng Lv
Principal Investigator
Peking University First Hospital

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

A Study to Evaluate the Long-Term Safety and Efficacy of HSK39297 Tablets in Primary IgA Nephropathy

IgA Nephropathy (IgAN)

Abroad (travel likely)RecruitingPHASE2

Beijing, China · Beijing, China

A Study of SHR-2173 in Participants With Primary IgA Nephropathy

Primary IgA Nephropathy

Abroad (travel likely)RecruitingPHASE2

Guangzhou, China · Shanghai, China

A Phase IIa Clinical Study of RG002C0106 Injection in Subjects With Primary IgA Nephropathy

IgA Nephropathy (IgAN)

Abroad (travel likely)RecruitingPHASE2

Beijing, China

Avacopan in Crescentic Immunoglobulin A Nephropathy (IgAN)

IgA Nephropathy (IgAN)

Abroad (travel likely)RecruitingPHASE2

Jacksonville, United States · Rochester, United States